At a glance
- According to the FAO/WHO definition, a probiotic is a live microorganism that confers a health benefit on the host when taken in adequate amounts; ISAPP reaffirmed this definition in 2014. [1]
- The result for one strain cannot be carried over to another strain; the generalization “probiotics are beneficial” is therefore not valid. [2]
- In children and adults using antibiotics, it reduces the risk of diarrhea on average; in acute infectious diarrhea in children, however, no difference was seen in trials at low risk of bias. [3] [5]
- Caution is needed in people with suppressed immunity or who are severely ill. [2]
- This guide does not recommend personal products or doses.
What are probiotics?
The FAO/WHO definition is as follows: a probiotic is “live microorganisms that, when administered in adequate amounts, confer a health benefit on the host.” The International Scientific Association for Probiotics and Prebiotics (ISAPP), at its 2014 expert meeting, still found this definition appropriate and stated that the term should be used more carefully to reduce confusion in the product market. [1]
This definition has two conditions: the microorganism must be alive and its benefit must be proven. A product having “probiotic” written on its label does not mean the second condition is met.
Why is the effect of a probiotic strain-specific?
Microorganisms are named by genus, species and strain. For example, in the recommendation texts of the American Gastroenterological Association (AGA) guideline, products are referred to by strain codes such as L. reuteri (DSM 17938 or ATCC 55730) and L. rhamnosus (ATCC 53103); the recommendation is not for all Lactobacillus species but for the strains or mixtures named. [6] Genus names are also changing: ISAPP’s fermented foods consensus states that Lactiplantibacillus plantarum was formerly named Lactobacillus plantarum. [9]
The safety review by Boyle and colleagues emphasizes the same point: the properties of probiotic species can be strain-specific, and the effect of one strain should not be generalized to other strains without confirmation by separate studies. [2] The Cochrane results below should therefore be read as an “average for all probiotics”: many different strains and mixtures are evaluated together.
What does CFU mean, is higher CFU better?
CFU (colony-forming unit; “kob” in Turkish sources) is a measure of the number of live microorganisms in a product. In the Cochrane review examining prevention of antibiotic-associated diarrhea in children, a prespecified subgroup analysis showed that doses of 5 billion CFU per day and above were more effective than lower doses (interaction P = 0.01); in the high-dose trials the diarrhea rate was 8% in the probiotic group and 23% in the control group. [3] This does not mean “higher CFU is better in every situation”: the result is valid for the products and strains in that review and for that situation; the authors of the review also state that the high-dose result needs to be confirmed by a large, well-designed multicenter trial. [3]
In which situations do probiotics work? Evidence summary
Results point in different directions by situation. Each row gives who was examined together with the limit of the evidence.
| Situation | Group examined | Result and limit |
|---|---|---|
| Antibiotic-associated diarrhea (children) | 33 RCTs, 6,352 children | Diarrhea 8% / 19% (RR 0.45); NNTB 9; moderate certainty. [3] |
| Prevention of C. difficile diarrhea | 38 RCTs, 13,179 people (children and adults) | 1.6% / 3.2% (RR 0.50); low certainty. [4] |
| Acute infectious diarrhea in children | 82 RCTs, 12,127 participants | No difference in diarrhea lasting ≥48 hours in trials at low risk of bias (RR 1.00). [5] |
| Upper respiratory tract infection | 23 RCTs, 6,950 participants | At least one infection RR 0.76; low certainty. [7] |
Diarrhea while using antibiotics
In children, Cochrane (2019) found the rate of antibiotic-associated diarrhea in 33 trials (6,352 participants) to be 8% in the probiotic group and 19% in the control group (RR 0.45; 95% CI 0.36–0.56); NNTB 9. The result stayed significant even in the analysis for missing data using the most unfavorable plausible assumptions (RR 0.61). The review states that no serious adverse event was attributed to probiotics, but that in observational reports outside the trials, serious events were reported in children with central catheters or suppressed immunity. [3]
The meta-analysis in adults also found an average risk reduction but reported that the effect was seen only in certain species and in trials where baseline diarrhea risk was not low; the numbers and limits are on the benefits page.
Clostridioides difficile
The 2025 Cochrane update includes 47 trials (15,260 participants). For C. difficile diarrhea, the event rate in 38 trials (13,179 participants) is 1.6% versus 3.2%; the evidence is of low certainty and the absolute difference is small (NNT 65). The review reports that in 28 trials the authors had a tie to a probiotic company or company support. The authors’ judgment that “short-term use is probably not associated with side effects” is for people who are not immunosuppressed and who are receiving systemic antibiotics. [4]
AGA distinguishes two separate situations. In those who already have C. difficile infection, it recommends probiotics only within a clinical trial. In adults and children receiving antibiotics, it gave a conditional, low-certainty recommendation in favor of the four named products (S. boulardii and three separate strain mixtures); those who are severely ill, or who value cost and the small risk, may find it reasonable not to use probiotics. [6]
Acute diarrhea in children: effect not shown
This is the section that reverses a commonly held belief. Cochrane’s 2020 update pooled 82 trials (12,127 participants; 11,526 children, 412 adults). In many trials the risk of bias was high or unclear and the results were highly variable. In trials at low risk for all bias indicators, there was no difference in the rate of diarrhea lasting 48 hours or longer (RR 1.00; 95% CI 0.91–1.09; 2 trials, 1,770 participants; moderate certainty); for the duration of diarrhea, the estimate was a shortening of 8.64 hours, but the interval ran from a shortening of 29.4 hours to a lengthening of 12.1 hours (6 trials; very low certainty). The authors therefore state that probiotics probably make little or no difference to the number of cases of diarrhea lasting 48 hours or longer and that it is uncertain whether they shorten the duration. [5]
Irritable bowel syndrome
In IBS, two sources are read in different directions: the American College of Gastroenterology’s (ACG) 2021 guideline gives a conditional recommendation against probiotics for global symptoms (evidence of very low certainty), while a 2014 meta-analysis found a mean reduction in symptoms but could not determine which strain was effective. The two sources and their limits are given side by side on the benefits page.
Other areas
Colic in breastfed infants, necrotizing enterocolitis in very preterm infants, allergy and eczema, upper respiratory tract infections, H. pylori treatment, weight and mood are each covered separately. AGA conditionally recommends specific strains and mixtures for preventing NEC in preterm infants with low birth weight; in Crohn’s disease and ulcerative colitis, it recommends use only within a clinical trial. [6]
Detailed guideProbiotic benefits: evidence for each claimDo probiotics strengthen immunity?
“Immunity” is a general claim; the measurable outcome is the frequency of infection. Cochrane’s 2022 update included 23 trials (6,950 participants; children aged 1 month–11 years, adults with a mean age of 37.3, older people with a mean age of 84.6) in the meta-analysis. The risk of having at least one upper respiratory tract infection was lower with probiotics (RR 0.76; 95% CI 0.67–0.87; 16 trials; low certainty); for three or more infections RR 0.59 (4 trials; moderate certainty); an episode of infection was a mean of 1.22 days shorter (low certainty). Most trials used one or two strains and gave 10⁹ or 10¹¹ CFU per day for more than three months. Trials in which the proportion receiving influenza vaccination exceeded 50% were excluded. [7] These findings do not support the conclusion that probiotics “strengthen immunity”; they show a small-to-moderate reduction in the number of infections under some conditions.
How is the information on the label read?
When reading a label, the information that relates to the evidence needs to be separated from the rest. The strain code (for example, genus, species and then a letter-number code) matters, because guideline recommendations and trial results are tied to that strain; the species name alone (such as “Lactobacillus”) does not carry a trial result. [6] [2] The CFU on the label is tied in Türkiye’s health claim condition to the threshold of “at least 1.0×10⁶ cfu/g” (“kob/g” in the Turkish text); this threshold is not proof of benefit but a product condition sought for the claim to be used. [11]
Should healthy people take probiotics?
A review evaluating the evidence on probiotic use in healthy people (Merenstein et al., 2024) concluded that specific probiotics could be considered by some people for certain indications — for example, supporting gut function while using antibiotics or reducing the risk of respiratory tract infection. The same review found no sufficient level of evidence to support unconditional, population-wide recommendations for the other preventive outcomes examined; mental, dental and immune health were outside the scope of this review. [12] In other words, continuous probiotic use by a healthy person “for gut flora” does not meet a proven need.
Are probiotics safe? Who should be careful?
According to Boyle and colleagues, the general safety record of probiotics is very good; however, they should be used with care in groups such as premature infants and those with immune deficiency. [2] In a case series examining the records of five university hospitals in Finland (2009–2018), at least 20 (43%) of 46 patients with Saccharomyces fungemia were using an S. boulardii probiotic; the odds ratio for bacteremia or candidemia compared with the control group was 14 (95% CI 4–44). This design does not show causality, but the association is strong; the authors state that the use of these products in patients whose gut integrity may be impaired should be evaluated carefully. [8] The Cochrane C. difficile review concludes that short-term probiotic use is unlikely to be associated with side effects in people receiving systemic antibiotics who are not immunosuppressed. [4]
Probiotics in Türkiye: a food supplement or a medicine?
In Türkiye, most probiotic products are food supplements; production and placing on the market are overseen by the Ministry of Agriculture and Forestry. The text in the TİTCK (Turkish Medicines and Medical Devices Agency) health claim list is as follows: a food supplement is not a medicine, cannot be used for preventing or treating diseases, and there is no food supplement approved by the Ministry of Health. [11]
The same list contains the “Probiotic microorganisms” claim with this text: “This product contains probiotic microorganisms. Probiotic microorganisms help regulate the digestive system and support the immune system.” The condition for the claim is that the product contain at least 1.0×10⁶ cfu/g (“kob/g” in the Turkish text) of live probiotic microorganisms. [11] The TİTCK re-evaluated these claims with its Office Approval (Makam Olur) dated September 27, 2024. According to the announcement, it was decided that the probiotic claim be changed to “Probiotic microorganisms contribute to balancing the gut microbiota” and that the condition be at least 1.0×10⁸ CFU/g of at least one species in the daily intake; the prebiotic component claim, on the other hand, was suspended on the grounds that there was no sufficient scientific evidence. In the same institution’s current full list, a note “has been suspended” appears next to both claims, with information that the evaluation is continuing; until the decision is finalized, existing products using these claims may use the wording only on their labels. [10] [11]
In the Ministry of Agriculture and Forestry’s Restricted Substances List for Food Supplements (last updated 21/09/2026), the “Probiotic microorganism” row gives a range of at least 1×10⁶ and at most 1×10¹⁰ cfu/day for both ages 4–10 and ages 11 and over. The row names the strains evaluated and found suitable under the application procedure and requires the strain to be declared on the label with its current taxonomic name and strain code. [13] This range is a product condition; it does not show that a given strain benefits a given condition.
Are yogurt, kefir and pickles probiotics?
Fermented foods can contain live cultures, but according to ISAPP a fermented food and a probiotic are not the same thing: for a food to be counted as a probiotic, the strain must be defined, benefit must have been shown in a human study and a sufficient number of live organisms must be present until the end of the product’s shelf life. In heat-treated fermented vegetables, no live microorganisms remain. [9]
Detailed guideWhich foods contain probiotics? Fermented foods tablePrebiotics and timing
Prebiotics are not live microorganisms but substrates selectively used by microorganisms; they are covered on a separate page. There is a separate guide on how probiotics relate to meals, antibiotics and duration.
Detailed guideWhat are prebiotics? Foods, evidence and limits Detailed guideWhen are probiotics taken? Meals, antibiotics and durationThis guide does not recommend personal products or doses. Use in severe illness, immune suppression, with a catheter, in pregnancy or in infants is assessed together with the physician.
What does the evidence say?
What it does and does not affectLimited or insufficient evidence
- CPrevention of Clostridioides difficile diarrheaIn Cochrane, relative risk is halved with low-certainty evidence; the absolute difference is small (1.6%). The authors’ assessment of side effects is for people who are not immunosuppressed.
- CIrritable bowel syndrome — evidence conflictingThe ACG 2021 gives a recommendation against probiotics for global symptoms (conditional, very low certainty); in a 2014 meta-analysis of 43 RCTs, symptoms decrease, and which strain is effective is unclear.
- CColic in breastfed infants (L. reuteri DSM 17938 only)In the individual data of four small RCTs (345 infants), crying time at day 21 was a mean of 25 minutes shorter; the effect is marked in breastfed infants and not significant in formula-fed infants.
- CNecrotizing enterocolitis in very preterm infantsCochrane: risk decreases with low-certainty evidence (RR 0.54); there may be little or no effect in extremely preterm infants. The AAP 2021 does not support routine use.
- CPrevention of upper respiratory tract infections (common cold)Cochrane 2022: RR 0.76 for having at least one infection (low certainty); infection duration a mean of 1.22 days shorter.
- CAdjunct to H. pylori eradication treatmentIn a 19-trial meta-analysis, eradication increases when added to bismuth quadruple therapy (OR 1.49).
- DPrevention of eczema in high-risk infantsWAO 2015: conditional recommendation, very low certainty; it was not shown to reduce allergy risk, and the net benefit comes from eczema.
- DWeight control — small mean changeIn an umbrella review, a mean reduction of 0.59 kg in body weight; the reliability of the evidence is low.
- DDepressive symptomsIn 19 trials, benefit was significant in patients with major depression and not significant in other patient groups and the general population.
What do the A–E grades mean?
The letter describes the strength of evidence for a specific claim, not the size of the benefit or a usage recommendation. E does not mean ineffectiveness has been proven.
- AStrong
- Established physiology (e.g. correcting a deficiency) or strong, consistent, direct human studies
- BModerate
- Supportive human evidence; small effect or some limitations
- CLimited
- A single randomised trial, mixed results or low-certainty human findings
- DInsufficient
- Small, uncontrolled or indirect evidence; not enough to judge
- ENo benefit shown / not studied in humans
- No benefit shown for the claim, or only animal or cell data exist
These grades are Half-Life Journal’s editorial evidence summary; they are not a formal GRADE rating or independent medical approval.
The letter shows evidence strength; it is not a score for positive effect or a usage recommendation.
Frequently asked questions
Does everyone need probiotics?
No. Probiotics are not nutrients; the body’s daily requirement is not defined. Proven benefits have been shown for specific strains and specific situations (for example, preventing diarrhea while on antibiotics). According to one review, there is no level of evidence to support an unconditional, population-wide recommendation for healthy people.
Do probiotics work against antibiotic diarrhea?
Yes, on average. In the Cochrane review including 33 trials in children, the frequency of diarrhea was 8% in the probiotic group and 19% in the control group (moderate-certainty evidence); in a 42-trial meta-analysis in adults, risk fell by 37%. The effect varies by product and strain.
Do probiotics shorten diarrhea in children?
According to Cochrane’s 2020 review, in large trials at low risk of bias there is no difference in the frequency of diarrhea lasting longer than 48 hours (RR 1.00); it is uncertain whether probiotics shorten the duration of diarrhea.
Are yogurt and kefir probiotics?
They contain live cultures, but according to ISAPP, for a food to be counted as a probiotic, strain-level identification, benefit proven in a human study and a sufficient number of live organisms throughout the product’s shelf life are required. A fermented food and a probiotic are not the same thing.
Who might be at risk from probiotics?
Caution is needed for people with suppressed immunity, those who are severely ill, those with a central venous catheter and premature babies. Cases of fungemia (yeast entering the blood) have been reported with products containing S. boulardii.
Sources
- Guideline / review Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. (2014)Back to text ↑
- Guideline / review Probiotic use in clinical practice: what are the risks? (2006)Back to text ↑
- Probiotics for the prevention of pediatric antibiotic-associated diarrhea. (2019)Back to text ↑
- Probiotics for the prevention of Clostridioides difficile-associated diarrhea in adults and children. (2025)Back to text ↑
- Probiotics for treating acute infectious diarrhoea. (2020)Back to text ↑
- Guideline / review AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders. (2020)Back to text ↑
- Probiotics for preventing acute upper respiratory tract infections. (2022)Back to text ↑
- Human study Fungemia and Other Fungal Infections Associated with Use of Saccharomyces boulardii Probiotic Supplements. (2021)Back to text ↑
- Guideline / review The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on fermented foods. (2021)Back to text ↑
- Institution TİTCK — Sağlık beyanı: probiyotik mikroorganizma ve prebiyotik bileşen beyanlarına ilişkin duyuru (Makam Olur 27.09.2024) (2024)Back to text ↑
- Institution TİTCK — Sağlık Beyanları Tam Liste (probiyotik mikroorganizmalar bölümü)Back to text ↑
- Guideline / review Is There Evidence to Support Probiotic Use for Healthy People? (2024)Back to text ↑
- Institution T.C. Tarım ve Orman Bakanlığı — Takviye Edici Gıdalar Kısıtlı Maddeler Listesi (son güncelleme 21/09/2026) (2026)Back to text ↑
Method: Institutional clinical guidance and relevant studies were compared. Each finding is presented with its population, outcome, sources and limitations. Independent medical review has not yet been completed.
Updated
This content is for information only and is not medical advice. It does not recommend doses, products or vendors. Talk to your clinician before making any health decision.
